Ten studies focused on therapeutic effects on prostate cancer, among which 6 published before 2000 reported objective response (6, 9–11, 13, 15), 2 reported PSA and testosterone decline, 1 reported nadir PSA and time to progression (TTP) (5), and 1 only reported testosterone decline (7). This evidence concerns the gene KLK3 and prostate cancer.